Boxer Capital Management, LLC
CIK 2018299 · View on SEC EDGAR ↗
- Portfolio value
- $1.3B
- Positions
- 63
- As of
- June 30, 2026
#2,020 of 9,443 by 13F value · top 21.4%
Portfolio value QoQ: +74.3% 13F does not disclose cash
- Top 10 holdings weight
- 65.15%
- Top 25 holdings weight
- 87.24%
- Positions above 1%
- 22
- Effective number of positions
- 11.3
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 2.82% Est. buys $339,903,926 · sells $29,424,652
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 55.8% still held
- New positions
- 12
- Increased
- 17
- Decreased
- 1
- Closed
- 3
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +203.1% · S&P 500: +28.7%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 96.2% · Options excluded: 0.0%
Sector breakdown
Healthcare
95.1%
Other/Unmapped
4.9%
Full portfolio 63 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. - Common Stock | $339,990,606 | 25.61% | 10,876,219 | $112,460,105 | |||
| RVMD Revolution Medicines, Inc. - Common Stock | $93,640,000 | 7.05% | 500,000 | $45,015,000 | |||
| ABVX Abivax SA - American Depositary Shares | $80,622,300 | 6.07% | 605,000 | $58,352,300 | Up ×3 | ||
| QURE uniQure N.V. - Ordinary Shares | $69,241,998 | 5.21% | 1,503,300 | $58,418,298 | Up ×2 | ||
| KOD Kodiak Sciences Inc - Common Stock | $57,567,296 | 4.34% | 1,477,600 | $5,685,976 | Up ×3 | ||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $49,204,897 | 3.71% | 429,100 | $21,794,158 | Up ×1 | ||
| DFTX Definium Therapeutics, Inc. - Common Shares | $46,969,440 | 3.54% | 998,500 | $35,657,790 | Up ×1 | ||
| REPL Replimune Group, Inc. - Common Stock | $44,091,810 | 3.32% | 3,983,000 | $35,103,060 | Up ×2 | ||
| CELC Celcuity Inc. - Common Stock | $43,577,368 | 3.28% | 416,530 | $17,895,868 | Up ×1 | ||
| QTTB Q32 Bio Inc. - Common Stock | $40,122,209 | 3.02% | 3,149,310 | Up ×1 | |||
| CAPR Capricor Therapeutics, Inc. - Common Stock | $33,595,356 | 2.53% | 1,395,156 | $15,659,356 | Up ×2 | ||
| PGEN Precigen, Inc. - Common Stock | $29,355,000 | 2.21% | 5,150,000 | $15,810,000 | Up ×3 | ||
| CORT Corcept Therapeutics Incorporated - Common Stock | $29,171,725 | 2.20% | 335,500 | $19,094,225 | Up ×1 | ||
| SRZN Surrozen, Inc. - Common Stock | $26,963,591 | 2.03% | 1,105,683 | $4,640,748 | Up ×2 | ||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $20,838,600 | 1.57% | 170,000 | $2,920,600 | |||
| VIR Vir Biotechnology, Inc. - Common Stock | $19,014,540 | 1.43% | 1,866,000 | $2,295,180 | |||
| PCVX Vaxcyte, Inc. - Common Stock | $18,892,250 | 1.42% | 325,000 | $6,500 | |||
| URGN UroGen Pharma Ltd. - Ordinary Shares | $18,400,000 | 1.39% | 500,000 | $9,410,000 | |||
| CRVS Corvus Pharmaceuticals, Inc. - Common Stock | $16,434,000 | 1.24% | 1,100,000 | $341,000 | |||
| PTCT PTC Therapeutics, Inc. - Common Stock | $16,314,000 | 1.23% | 200,000 | $2,688,000 | |||
| PRAX Praxis Precision Medicines, Inc. - Common Stock | $15,553,339 | 1.17% | 46,457 | $585,358 | |||
| AMLX Amylyx Pharmaceuticals, Inc. - Common Stock | $14,368,000 | 1.08% | 800,000 | $3,248,000 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $12,766,000 | 0.96% | 1,300,000 | $9,801,500 | Up ×1 | ||
| IRD Opus Genetics, Inc. - Common Stock | $11,569,650 | 0.87% | 2,815,000 | $1,332,150 | Up ×1 | ||
| PALI Palisade Bio, Inc. - Common Stock | $10,031,739 | 0.76% | 4,799,875 | $1,631,958 | |||
| APGE Apogee Therapeutics, Inc. - Common Stock | $9,291,100 | 0.70% | 70,000 | $3,399,200 | |||
| SYRE Spyre Therapeutics, Inc. - Common Stock | $8,878,000 | 0.67% | 100,000 | ||||
| COGT Cogent Biosciences, Inc. - Common Stock | $8,707,500 | 0.66% | 225,000 | $47,250 | |||
| CYTK Cytokinetics, Incorporated - Common Stock | $8,519,000 | 0.64% | 100,000 | $1,928,000 | |||
| RLAY Relay Therapeutics, Inc. - Common Stock | $8,419,500 | 0.63% | 450,000 | ||||
| CBIOXXXX | $8,166,348 | 0.62% | 453,686 | $-167,864 | |||
| CTNM Contineum Therapeutics, Inc. - Common stock | $8,096,660 | 0.61% | 494,000 | $1,645,020 | |||
| KZIA Kazia Therapeutics Limited - American Depositary Shares | $7,884,800 | 0.59% | 560,000 | Up ×1 | |||
| STTK Shattuck Labs, Inc. - Common Stock | $6,940,000 | 0.52% | 1,000,000 | Up ×1 | |||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $6,930,000 | 0.52% | 375,000 | $2,451,000 | Up ×3 | ||
| FBRX Forte Biosciences, Inc. - Common Stock | $5,833,125 | 0.44% | 274,500 | Up ×1 | |||
| RLMD Relmada Therapeutics, Inc. - Common Stock | $5,827,374 | 0.44% | 842,106 | $-33,684 | |||
| MLTX MoonLake Immunotherapeutics - Class A Ordinary Shares | $5,354,250 | 0.40% | 275,000 | $228,250 | |||
| ZURA Zura Bio Limited - Class A Ordinary shares | $5,310,000 | 0.40% | 900,000 | $-45,000 | |||
| HELP Cybin Inc. - Common Stock | $5,221,900 | 0.39% | 790,000 | $2,149,900 | Up ×1 | ||
| Unknown issuer (CUSIP: 67613T104) | $5,145,250 | 0.39% | 275,000 | Up ×1 | |||
| IMTX Immatics N.V. - Ordinary Shares | $4,811,750 | 0.36% | 475,000 | Up ×1 | |||
| SNSE Sensei Biotherapeutics, Inc. - Common Stock | $4,512,625 | 0.34% | 180,505 | Up ×1 | |||
| GPCR Structure Therapeutics Inc. - American Depositary Shares | $4,025,250 | 0.30% | 75,000 | $410,250 | |||
| ORIC Oric Pharmaceuticals, Inc. - Common Stock | $3,790,500 | 0.29% | 350,000 | $1,554,245 | Up ×1 | ||
| ANTX AN2 Therapeutics, Inc. - Common Stock | $3,625,329 | 0.27% | 749,035 | $1,063,629 | |||
| NMRA Neumora Therapeutics, Inc. - Common Stock | $3,400,000 | 0.26% | 2,000,000 | Up ×1 | |||
| INO Inovio Pharmaceuticals, Inc. - Common Stock | $3,129,493 | 0.24% | 2,844,994 | $-994,519 | Up ×1 | ||
| ALLO Allogene Therapeutics, Inc. - Common Stock | $3,120,000 | 0.23% | 1,500,000 | $-3,529,000 | Down ×1 | ||
| SLDB Solid Biosciences Inc. - Common Stock | $2,997,000 | 0.23% | 300,000 | $837,000 | |||
| KPTI Karyopharm Therapeutics Inc. - Common Stock | $2,955,777 | 0.22% | 302,536 | $1,270,651 | |||
| CLNN Clene Inc. - Common Stock | $2,939,105 | 0.22% | 477,515 | $584,956 | |||
| SRPT Sarepta Therapeutics, Inc. - Common Stock | $2,695,500 | 0.20% | 150,000 | $-568,500 | |||
| MPLT MapLight Therapeutics, Inc. - Common Stock | $2,688,000 | 0.20% | 75,000 | Up ×1 | |||
| NRIX Nurix Therapeutics, Inc. - Common stock | $2,426,000 | 0.18% | 100,000 | $876,000 | |||
| LBRX LB Pharmaceuticals Inc - Common Stock | $2,271,850 | 0.17% | 70,000 | $545,650 | |||
| EDSA Edesa Biotech, Inc. - Common Shares | $1,666,650 | 0.13% | 205,000 | Up ×1 | |||
| IVVD Invivyd, Inc. - Common Stock | $1,308,600 | 0.10% | 1,500,000 | $-641,400 | |||
| UPB Upstream Bio, Inc. - Common Stock | $1,038,000 | 0.08% | 150,000 | $-312,000 | |||
| MIST Milestone Pharmaceuticals Inc. - Common Shares | $893,332 | 0.07% | 666,666 | $99,999 | |||
| PEPG PepGen Inc. - Common Stock | $491,206 | 0.04% | 272,892 | $8,187 | |||
| RGNX REGENXBIO Inc. - Common Stock | $179,700 | 0.01% | 15,000 | $54,000 | |||
| SRZNW Surrozen, Inc. - Warrant | $1,067 | 0.00% | 66,666 | $0 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| QTTB | $40,122,209 | 3,149,310 | 3.02% |
| SYRE | $8,878,000 | 100,000 | 0.67% |
| RLAY | $8,419,500 | 450,000 | 0.63% |
| KZIA | $7,884,800 | 560,000 | 0.59% |
| STTK | $6,940,000 | 1,000,000 | 0.52% |
| FBRX | $5,833,125 | 274,500 | 0.44% |
| Unknown issuer (CUSIP: 67613T104) | $5,145,250 | 275,000 | 0.39% |
| IMTX | $4,811,750 | 475,000 | 0.36% |
| SNSE | $4,512,625 | 180,505 | 0.34% |
| NMRA | $3,400,000 | 2,000,000 | 0.26% |
| MPLT | $2,688,000 | 75,000 | 0.20% |
| EDSA | $1,666,650 | 205,000 | 0.13% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| TNGX | Price move only | +0 | +$112.5M |
| ABVX | Bought more | +405K | +$58.4M |
| RVMD | Price move only | +0 | +$45.0M |
| DFTX | Bought more | +400K | +$35.7M |
| REPL | Bought more | +2.8M | +$35.1M |
| KYMR | Bought more | +100K | +$21.8M |
| CORT | Bought more | +86K | +$19.1M |
| CELC | Bought more | +192K | +$17.9M |
| PGEN | Bought more | +1.6M | +$15.8M |
| CAPR | Bought more | +805K | +$15.7M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| SWTX | March 31, 2025 | 3,421,541 | $123,620,276 | No longer tracked |
| AXSM | March 31, 2025 | 470,000 | $39,766,700 | 85.5% |
| SRRK | March 31, 2025 | 750,000 | $32,415,000 | 72.3% |
| NUVL | June 30, 2025 | 450,000 | $31,914,000 | No longer tracked |
| TYRA | March 31, 2025 | 2,027,678 | $28,184,724 | 178.5% |
| RNA | June 30, 2025 | 865,000 | $25,534,800 | -52.0% |
| ANAB | June 30, 2025 | 1,300,000 | $24,167,000 | 161.7% |
| RCUS | March 31, 2025 | 1,602,200 | $23,856,758 | 271.5% |
| GERN | March 31, 2025 | 6,000,000 | $21,240,000 | -1.6% |
| THRD | March 31, 2025 | 2,000,000 | $20,580,000 | No longer tracked |
| IMVT | March 31, 2025 | 825,000 | $20,435,250 | 159.0% |
| ARVN | March 31, 2025 | 1,058,614 | $20,293,630 | 34.9% |
| XENE | June 30, 2025 | 600,000 | $20,130,000 | 97.0% |
| TERN | June 30, 2026 | 375,000 | $19,770,000 | No longer tracked |
| PSTX | March 31, 2025 | 2,000,000 | $19,200,000 | No longer tracked |
| RCKT | March 31, 2025 | 1,466,051 | $18,428,261 | -47.2% |
| APLS | June 30, 2025 | 713,000 | $15,593,310 | No longer tracked |
| CMRX | June 30, 2025 | 1,810,000 | $15,403,100 | No longer tracked |
| GPCR | March 31, 2025 | 500,000 | $13,560,000 | 207.6% |
| KALV | March 31, 2025 | 1,590,000 | $13,467,300 | No longer tracked |
| ELVN | June 30, 2025 | 671,358 | $13,212,325 | 188.8% |
| CDTX | March 31, 2026 | 53,000 | $11,707,170 | No longer tracked |
| MRUS | Dec. 31, 2025 | 120,000 | $11,298,000 | No longer tracked |
| CGEM | March 31, 2025 | 907,895 | $11,058,161 | 187.5% |
| SYRE | March 31, 2025 | 466,680 | $10,864,310 | 556.6% |
| ORIC | June 30, 2025 | 1,732,571 | $9,667,746 | 41.0% |
| DAWN | June 30, 2025 | 1,189,943 | $9,436,248 | No longer tracked |
| PRTA | June 30, 2025 | 690,000 | $8,538,750 | 47.6% |
| ITOS | Sept. 30, 2025 | 825,000 | $8,225,250 | No longer tracked |
| MNMD | March 31, 2026 | 598,500 | $8,013,915 | No longer tracked |
| JSPR | March 31, 2025 | 350,000 | $7,483,000 | -82.6% |
| ITOS | March 31, 2025 | 946,915 | $7,272,307 | No longer tracked |
| NKTR | Dec. 31, 2025 | 125,000 | $7,112,500 | 76.9% |
| LEGN | June 30, 2025 | 200,000 | $6,786,000 | -36.8% |
| SLNO | June 30, 2026 | 200,000 | $6,696,000 | No longer tracked |
| IOVA | March 31, 2025 | 750,000 | $5,550,000 | 148.3% |
| CBIO | March 31, 2026 | 453,686 | $5,380,716 | -8.3% |
| SLDB | June 30, 2025 | 1,240,700 | $4,590,590 | 90.7% |
| SMMT | March 31, 2025 | 250,000 | $4,461,250 | -34.8% |
| TERN | March 31, 2025 | 752,000 | $4,166,080 | No longer tracked |
| KROS | March 31, 2025 | 250,000 | $3,957,500 | 5.7% |
| APGE | March 31, 2025 | 86,000 | $3,895,800 | 260.6% |
| OLMA | March 31, 2025 | 650,000 | $3,789,500 | 191.2% |
| MRSN | March 31, 2025 | 2,635,000 | $3,768,050 | No longer tracked |
| DNLI | Dec. 31, 2025 | 250,000 | $3,630,000 | 52.2% |
| DNLI | June 30, 2025 | 250,000 | $3,400,000 | 79.6% |
| SANA | March 31, 2025 | 1,545,000 | $2,518,350 | 129.5% |
| BCAX | March 31, 2025 | 135,000 | $2,351,700 | 93.5% |
| RLAY | March 31, 2025 | 536,132 | $2,208,864 | 659.4% |
| PRLD | June 30, 2025 | 2,108,014 | $1,623,171 | 621.9% |
| ZNTL | March 31, 2025 | 450,000 | $1,363,500 | 143.4% |
| TIL | Dec. 31, 2025 | 60,700 | $1,084,102 | -32.8% |
| BDTX | March 31, 2025 | 506,000 | $1,082,840 | 38.7% |
| OBIO | March 31, 2025 | 238,193 | $952,772 | 27.8% |
| ZURA | March 31, 2025 | 300,000 | $750,000 | 343.4% |
| MIST | March 31, 2025 | 309,007 | $729,257 | 36.9% |
| KALV | June 30, 2026 | 20,400 | $410,652 | No longer tracked |
| BCAB | March 31, 2025 | 686,347 | $405,768 | 856.8% |
| BOLD | June 30, 2025 | 250,000 | $377,500 | 186.1% |
| CLYM | June 30, 2025 | 145,000 | $176,900 | 1281.5% |
| DBVT | March 31, 2025 | 50,000 | $154,500 | 111.0% |
| NUVBWS | March 31, 2026 | 266,666 | $88,000 | No longer tracked |